Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 454 participants.
Also called NCT03768427
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 454 participants
- Sponsor
- Registry
-
NCT03768427
-
- Other papers using this trial's data
- Efficacy and Tolerability of Ezetimibe/Atorvastatin Fixed-dose Combination Versus Atorvastatin Monotherapy in Hypercholesterolemia: A Phase III, Randomized, Active-controlled Study in Chinese Patients
- LDL-C Goal Attainment with Fixed-Dose Ezetimibe and Atorvastatin Versus High-Dose Atorvastatin in Chinese Patients: Subgroup Analysis of a Randomized Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03768427. Randomized; double masking; primary purpose treatment. Start 2019-05-27 (actual); primary completion 2021-03-17 (actual). Results posted on 2023-02-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)
- Condition
- Hypercholesterolemia
- Intervention (Combination product)
- EZ 10 mg/Ator 10 mg
- Intervention (Combination product)
- EZ 10 mg/Ator 20 mg
- Intervention (Drug)
- Atorvastatin
- Intervention (Drug)
- Placebo for FDC EZ/Ator
- Intervention (Drug)
- Placebo for atorvastatin
- Lead sponsor
- Organon and Co
Record details
- Record id
cardio:ct-nct03768427- Content hash
54b8cebe0c77865fb360b4a208c7dd67cb35fc35e970aee48eaa25016fddcf28